Abstract
Unstable angina (UA) is a clinically common coronary heart disease. Zhishi xiebai guizhi decoction (ZXGD) has been widely used in the management of UA, although its effective evidence is not clear and there is no systematic review regarding its efficacy and safety. Therefore, we conduct this systematic review protocol to evaluate the efficacy and safety of ZXGD in the treatment of UA. We will search the following electronic databases: Cochrane Library, Web of Science, PubMed, EBASE, Springer, WHO International Clinical Trial Registration Platform, China Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP), and Wan-fang database from their inception to October 2018. Only randomized controlled trials (RCTs) published in English and Chinese will be included. Continuous data will be expressed as mean difference or standard mean difference, and dichotomous data relative as risk. Study selection, data extraction, and assessment with risk of bias and data analysis will be performed by two independent authors. RevMan software version 5.3 will be used for meta-analysis. This study will provide high-quality evidence of ZXGD in the treatment of UA from the following aspects, including clinical efficacy, blood lipids, Seattle angina scale, electrocardiogram improvement, ST-segment depression, left ventricular ejection fraction, angina duration, and adverse events. This systematic review will provide a basis for judging whether ZXGD is an effective intervention for UA or not. PROSPERO CRD 42018115528.
Highlights
Unstable angina (UA) is one serious type of coronary heart disease between stable angina and acute myocardial infarction (AMI), with an abrupt onset, complex condition, and extraordinarily rapid progression, which can evolve into AMI and sudden cardiac death.[1,2]
randomized controlled trials (RCTs) of Zhishi xiebai guizhi decoction (ZXGD) in the treatment of UA published in Chinese and English, whether blinded or not, will be included
Patients with UA (18 years of age and older) must meet the diagnostic criteria established by 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction.[8]
Summary
Unstable angina (UA) is one serious type of coronary heart disease between stable angina and acute myocardial infarction (AMI), with an abrupt onset, complex condition, and extraordinarily rapid progression, which can evolve into AMI and sudden cardiac death.[1,2] UA threatens the life safety of patients seriously with high disability rate and mortality.[3,4,5] With the development of social economy, the change of residents’ lifestyle, the aging of population structure, the increase of life pressure and the reduction of sports activities, the incidence rate, and mortality rate are increasing year by year, resulting a threat to human life and health. In China, cardiovascular mortality remains the highest, higher than cancer and other diseases.[6,7] The guidelines for the management of UA recommend nitrates, b-blockers, and angiotensin-converting enzyme inhibitors.[8] There is definite effect for modern medicine in treating UA, adverse events are still inevitable. Zhishi xiebai guizhi decoction (ZXGD) has been widely used in the management of UA, its effective evidence is not clear and there is no systematic review regarding its efficacy and safety.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
